{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:33:58Z","timestamp":1783636438597,"version":"3.55.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enterococcus faecalis isolates with a daptomycin minimum inhibitory concentration (MIC) of 4\u2005mg\/L are classified as intermediate by the Clinical and Laboratory Standards Institute (CLSI). There is limited evidence to guide the use of high-dose daptomycin for these infections when alternative therapy options cannot be used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the rate of clinical failure of E. faecalis invasive infections with a daptomycin MIC of 4\u2005mg\/L treated with high-dose daptomycin or best alternative therapy (BAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-centre, retrospective, observational, cross-sectional study that compared high-dose daptomycin to BAT for invasive E. faecalis infections. High-dose daptomycin was defined as \u22658\u2005mg\/kg\/dose. The primary outcome was clinical failure, a composite endpoint including switch from definitive to alternative therapy secondary to clinical decline, infection-related hospital readmission while on definitive treatment for the index infection, or infection-related mortality within 30\u2005days of definitive therapy completion. High-dose daptomycin versus BAT groups were matched and compared in a 1:3 ratio based on initial source of the positive E. faecalis isolate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 112 patients included, 28 patients received daptomycin and 84 received BAT. There was no difference in the primary outcome of clinical failure between the daptomycin and BAT groups (7% versus 5%, P\u200a=\u200a0.64). All-cause mortality was similar between the daptomycin and BAT groups (11% versus 10%, P\u200a=\u200a1.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was no difference observed in clinical failure rates between patients treated with high-dose daptomycin versus BAT. All-cause mortality was also similar between the groups. Further studies are needed to confirm these findings in high-burden E. faecalis infections with intermediate daptomycin susceptibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag179","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:39:42Z","timestamp":1778067582000},"source":"Crossref","is-referenced-by-count":1,"title":["High-dose daptomycin for the treatment of invasive infections due to\n                    <i>Enterococcus faecalis<\/i>\n                    isolates with intermediate susceptibility"],"prefix":"10.1093","volume":"81","author":[{"given":"Sidney","family":"Drake","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center , 410 W 10th Ave, Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-2225","authenticated-orcid":false,"given":"Jessica","family":"Leininger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center , 410 W 10th Ave, Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Bazan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Ohio State University College of Medicine , 370 W 9th Ave, Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-5512","authenticated-orcid":false,"given":"Kelci","family":"Coe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Ohio State University College of Medicine , 370 W 9th Ave, Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-4850","authenticated-orcid":false,"given":"Lynn","family":"Wardlow","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center , 410 W 10th Ave, Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026052202043540600_dkag179-B1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40121-019-00261-w","article-title":"Should high-dose daptomycin be an alternative treatment regimen for enterococcal endocarditis?","volume":"8","author":"Peghin","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2026052202043540600_dkag179-B2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/cid\/ciz845","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026052202043540600_dkag179-B3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026052202043540600_dkag179-B4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026052202043540600_dkag179-B5","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052202043540600_dkag179-B6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026052202043540600_dkag179-B7","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"REDCap consortium, the REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026052202043540600_dkag179-B8","doi-asserted-by":"publisher","first-page":"890.e1","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2026052202043540600_dkag179-B9","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/jac\/dku004","article-title":"Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy","volume":"69","author":"Cer\u00f3n","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026052202043540600_dkag179-B10","year":"2025"},{"key":"2026052202043540600_dkag179-B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijid.2014.02.012","article-title":"Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study","volume":"26","author":"Billington","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026052202043540600_dkag179-B12","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00843-21","article-title":"Antimicrobial susceptibility testing for enterococci","volume":"60","author":"Khan","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026052202043540600_dkag179-B13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa064","article-title":"Infectious diseases consultation is associated with decreased mortality in enterococcal bloodstream infections","volume":"7","author":"Lee","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag179\/68365247\/dkag179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag179\/68365247\/dkag179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:04:42Z","timestamp":1779429882000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag179\/8690403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag179","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag179"}}